Biomarkers in Predicting Treatment Response in Samples From Patients With Early-Stage Non-Small Cell Lung Cancer Previously Treated With Adjuvant Chemotherapy

ConditionsStage IA Non-small Cell Lung Cancer Stage IB Non-small Cell Lung Cancer Stage IIA Non-small Cell Lung Cancer Stage IIB Non-small Cell Lung Cancer Stage IIIA Non-small Cell Lung Cancer

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorNational Cancer Institute (NCI)

About this trial

This research trial studies biomarkers in predicting treatment response in samples from patients with early-stage non-small cell lung cancer previously treated with adjuvant chemotherapy. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

Eligibility criteria

Qualifiers

International Adjuvant Lung Cancer Trail (IALT)

Cancer and Leukemia Group B (CALGB)-9633

CAN-NCIC-BR10

Adjuvant Navelbine International Trialist Association (ANITA)

Disqualifiers

None

Trial design

Treatments tested in this trial

medical chart review
laboratory biomarker analysis

Treatment groups

950 Participants

are divided into 1 treatment group

Sponsors and collaborators

National Cancer Institute (NCI)

Lead sponsor

Source ClinicalTrials.gov